Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards

Pharmacogenomics Journal

Volumn 4, Issue 6, 2004, Pages 403-406

  Llerena, A ^a,b   Dorado, P ^b   O'Kirwan, F ^a   Jepson, R ^a   Licinio, J ^a   Wong, M L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

CYP2C9; Hispanics; Mexican Americans; Pharmacogenetics; Spaniards

Indexed keywords

CYTOCHROME P450 2C9;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOME ANALYSIS; GENOTYPE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POPULATION GENETICS; PRIORITY JOURNAL; SPAIN;

ADULT; ALLELES; ARYL HYDROCARBON HYDROXYLASES; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; HUMANS; MALE; MEXICAN AMERICANS; MIDDLE AGED; SPAIN;

EID: 10044225576     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500278     Document Type: Article

References (30)

1. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29: 413-580.
2. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42.
3. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Inter-individual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
4. Goldstein JA, de Marais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4 285-299.
5. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-538.
6. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-355.
7. Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 2003; 33(Suppl 2): 23-30.
8. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-263.
9. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54: 1257-1270.
10. Dorado P, Berecz R, Norberto MJ, Yasar U, Dahl ML, LLerena A. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol 2003; 59: 221-225.
11. Xie HG, Prasad H, Landau R, Kim RB, Cai WM, Ieiri I et al. Frequency of the defective CYP2C9 variant alleles in different ethnic groups. Clin Pharmacol Ther 2002; 71: P102.
12. Machorro-Lazo MV, Flores-Martínez SE, García-Zapién AG, Mújica-López KI, Morán-Moguel MC, Sá nchez-Corona J. Genetic frequency of the variant CYP2C9*2 in Western Mexican Mestizos. HGM 2003; Posters Abstracts, Cancún 2003. (http://hgm2003.hgu.mrc.ac.uk).
13. Yasar Ü, Forslund-Bergengren C, Tybring G, Dorado P, LLerena A, Sjoqvist F et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002; 71: 89-98.
14. Griskevicius L, Yasar U, Sandberg M, Hidestrand M, Eliasson E, Tybring G et al. Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol 2003; 59: 103-109.
15. Imai J, Ieiri I, Mamiya K, Miyahara S, Furuumi H, Nanba E et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 2000; 10: 85-89.
16. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmocogenetics 2001; 11: 803-808.
17. Yasar U, Aklillu E, Canaparo R, Sandberg M, Sayi J, Roh HK et al. Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations. Eur J Clin Pharmacol 2002; 58: 555-558.
18. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P-450 CYP2C9 locus. Pharmacogenetics 1996; 6: 429-439.
19. Scordo MG, Aklillu E, Yasar Ü, Dahl M-L, Spina E, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P-450 2C9 in a Caucasian and a Black-African population. Br J Clin Pharmacol 2001; 52: 447-451.
20. Yasar Ü, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254: 628-631, Erratum in: Biochem Biophys Res Commun 1999; 258: 227.
21. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001; 60: 382-387.
22. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341-349.
23. Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS. Cytochrome P-4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol 2001; 79: 841-847.
24. Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS et al. Allele and genotype frequencies of polymorphic cytochromes P-450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 2002; 53: 596-603.
25. Peyvandi F, Spreafico M, Karimi M, Zeinali S, Mannucci PM, Bianchi Bonomi A. Allele frequency of CYP2C9 gene polymorphisms in Iran. Thromb Haemost 2002; 88: 874-875.
26. Aynacioglu AS, Brockmoller J, Bauer S, Sachse C, Guzelbey P, Ongen Z et al. Frequency of cytochrome P-450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48: 409-415.
27. Wang SL, Huang J, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5: 37-42.
28. Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P-450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monitor 1998; 20: 243-247.
29. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997; 7 405-409.
30. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY et al. Frequency of cytochrome P-450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001; 51: 277-280.